Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mutated protein combination tied to excessive sugar production

19.05.2003


Study identifies potential target for diabetes drugs



Researchers at Dana-Farber Cancer Institute have traced runaway sugar production in the liver – an important feature of diabetes – to flaws in a two-protein combination at the heart of a molecular switch that responds to insulin.

The findings, to be posted by the journal Nature on its Web site on May 18, suggest that drugs designed to block the interaction of the two switch proteins might be effective in treating diabetes, and with few side effects.


Building on their discovery of this master switch in fall 2001, scientists led by Dana-Farber’s Bruce Spiegelman, PhD, found that two previously known proteins in mice must “dock,” one on top of the other, to enable the switch to turn on genes that initiate the liver’s sugar-making process. Furthermore, when mutations cause a flaw in one of the proteins, the switch no longer can respond to insulin, the hormone that normally regulates sugar manufacture in the liver.

“The actual molecular connections between the proteins are potential targets for diabetic therapy,” says Spiegelman, the paper’s senior author. It may be possible to design an oral drug that could block the joining of the two proteins – PGC-1alpha and FOXO1 – when the switch is stuck in the “on” position.

The liver’s manufacture of sugar from raw materials, a process called gluconeogenesis, is designed to provide the body (especially the brain) with necessary glucose when the person has been fasting and isn’t obtaining the sugar from food. Glucagon and glucocorticoid hormones initiate the process on by sending signals to liver cells, triggering activity (DNA transcription) in genes that set gluconeogenesis in motion.

Insulin, produced in the pancreas, has the opposite effect, turning off gluconeogenesis when normal feeding resumes. Insulin activates the insulin receptors on liver cells’ surfaces, which send signals into the cells’ nuclei where they are received by the switch made up of the PGC-1alpha and FOXO1 proteins.

FOXO1 protein, known as a transcription factor, binds directly to the DNA molecules of the gluconeogenesis genes, causing them to copy their genetic blueprints into RNA. PGC-1alpha does not directly bind to the DNA, but instead docks onto the FOXO1 protein. Together, “they area a powerful, insulin-sensitive switch” for gluconeogenesis, says Spiegelman. “PGC-1 provides the horsepower, and FOXO1 is the insulin-sensitive receiver” of signals.

In a series of experiments with transgenic mice, Spiegelman and his colleagues showed that if a mutation occurs in the gene producing FOXO1, it results in an abnormal FOXO1 protein that no longer is sensitive to insulin. Consequently, the switch fails and the liver overproduces glucose, which spills into the blood and can damage vital organs and nerves.

In his previous Nature paper [Sept. 13, 2001] Spiegelman demonstrated that the PGC-1alpha protein was the long-sought switch for gluconeogenesis, but how that protein worked with FOXO1 wasn’t clear. At the time, Spiegelman suggested that blocking PGC-1alpha might be a new therapeutic strategy. He now says that targeting just the combination of PGC-1alpha and FOXO1 would be a more finely pointed tool with fewer unwanted effects.

“What’s exciting about this paper is that is unifies two fields,” commented Spiegelman, who is also a professor of cell biology at Harvard Medical School. “One was the discovery of the signaling pathway from the insulin receptor to the FOXO1 protein – and this was found in worms. The other was the work that led to the identification of PGC-1alpha as the switch for gluconeogenesis. Now we know that it is the complex of PGC-1alpha and FOXO1 that is important.”



The research was funded in part by the National Institutes of Health.

Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Bill Schaller | EurekAlert!
Further information:
http://www.dfci.harvard.edu/

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>